Rodríguez VM, Serna HJC, Gil AM, Palacios SGC

Language: Spanish
References: 10
Page: 35-39
PDF size: 213.03 Kb.

ABSTRACT

Background Allergic rhinitis is a chronic inflammation of the nasal mucosa by a type I hypersensitivity mechanism. The treatment of choice are the nasal steroids; however, the application of intraturbinal type A botulinum toxin (BTX-A) provides an effective treatment for long term patients with allergic rhinitis.
Objective To compare the effectiveness of the application of intraturbinal BTX-A versus the medical treatment with antihistamines and nasal steroids.
Methods Open randomized controlled trial in adult patients with allergic rhinitis, randomly assigned to three groups: group 1, 10 U BTX-A in bilateral inferior turbinates; group 2, 5 U BTX-A in bilateral inferior and middle turbinates; group 3, saline solution in inferior turbinates + 10 mg loratadine and nasal mometasone spray. Treatment response was assessed by the Total Nasal Symptom Scores 7, 14 and 21 days after application.
Results Thirty-nine patients were enrolled, group 1: 12 patients, group 2: 12 patients, group 3: 15 patients. There was a significant decrease in the severity of nasal symptoms in patients from groups 1 and 3 (p ‹ 0.05), with no significant evidence in patients from group 2. There weren’t any complications.
Conclusions Ten U of BT X-A on inferior turbinates is more effective than the treatment of loratadine + nasal mometasone spray in allergic rhinitis for 21 days, it is safe, well tolerated and provides comfort for the patient as it is done in one intervention.

REFERENCES

1. Bailey BJ, Johnson JT, Newlands SD. Head and Neck Surgery-Otolaryngology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

2. Marple BF, Fornadley JA, Patel AA, Fineman SM, American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136:S107-S124.

3. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-476.

4. Singer C. Indications and management of botulinum toxin. Rev Neurol 1999;29:157-162.

5. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8:21-29.

6. Chu MW, Lieser JD, Sinacori JT. Use of botulinum toxin type A for chronic cough: a neuropathic model. Arch Otolaryngol Head Neck Surg 2010;136:447-452.

7. Yang TY, Jung YG, Kim YH, Jang TY. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg 2008;139:367-371.

8. Unal M, Sevim S, Doğu O, Vayisoğlu Y, Kanik A. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol 2003;123:1060-1063.

9. Kim KS, Kim SS, Yoon JH, Han JW. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 1998;112:248-251.

10. Haahr M. RANDOM.ORG-List randomizer [Internet]. School of Computer Science and Statistics, Irlanda. 1998. Availble from: http://www.random.org/lists/